Funder: Breakthrough T1D
Due Dates: January 10, 2025 (Letter of Intent) | February 21, 2025 (Full proposal)
Funding Amounts: Up to $300,000 per year for 2 years; larger budgets possible with prior approval.
Summary: Supports research advancing technologies that improve survival and engraftment of insulin-producing cells at alternative transplantation sites for type 1 diabetes cell therapy.
Key Information: Genetic modification of transplanted cells and early-stage encapsulation device development are not eligible.